Circulating CD45+/CD3+ lymphocyte-derived microparticles map lipid-rich atherosclerotic plaques in familial hypercholesterolaemia patients

Circulating microparticles (cMPs) seem to play important roles in vascular function. Beyond markers of activated cells, cMPs may have potential paracrine functions and influence atherosclerosis. Here, our objective was to characterise a) the abundance and phenotype of cMPs in stable statin-treated heterozygous familial hypercholesterolaemia (FH) patients exposed to life-long hypercholesterolaemia and b) the principal phenotype associated to lipid-rich atherosclerotic plaques in hFH-patients with significant atherosclerotic plaque burden. An age/gender/treatment-matched group of adult-onset non-FH hypercholesterolaemic patients (n=37/group) was comparatively analysed. cMPs were characterised by flow cytometry using annexin-V and cell surface-specific antibodies. Our study shows that LLT-FH patients had higher overall cMP-numbers (p<0.005) than LLT-non-FH patients. Endothelial cell-shed cMPs were also significantly higherin FH (p<0.0005). Within the leukocyte-derived cMP-subpopulations, FH-patients had significantly higher lymphocyte- and monocyte-derived cMP-numbers as well as cMPs carrying leukocyte-activation markers. Normalisation of cMPs by LDL levels did not affect cMP number or phenotype, indicating that the proinflammatory effect was derived from chronic vascular damage. Levels of AV+-total, CD45+-pan-leukocyte and CD45+/CD3+-lymphocyte-derived cMPs were significantly higher in FH-patients with subclinical lipid-rich atherosclerotic plaques than fibrous plaques. Levels of CD45+/CD3+-lymphocyte-MPs above 20,000/ml could differentiate between FH-patients with lipidic or non-lipidic plaques (area under the ROC curve of 0.803, 95%CI: 0.641-0.965, p=0.008). In summary, in this snapshot cross-sectional study cMP concentration and phenotype in FH differed markedly from non-FH hypercholesterolaemia. Patients with life-long high LDL exposure have higher endothelial activation and higher proinflammatory profile, even under current state-of-the-art LLT. cMPs carrying lymphocyte-epitopes appear as markers of lipid-rich atherosclerotic plaques in FH.

[1]  Christian Weber,et al.  Microparticles: Protagonists of a Novel Communication Network for Intercellular Information Exchange , 2010, Circulation research.

[2]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[3]  R. Bertina,et al.  Pre-analytical and analytical issues in the analysis of blood microparticles , 2010, Thrombosis and Haemostasis.

[4]  Rodrigo Alonso,et al.  Lipid-lowering therapy with statins reduces microparticle shedding from endothelium, platelets and inflammatory cells , 2013, Thrombosis and Haemostasis.

[5]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[6]  R. Westendorp,et al.  Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. , 2000, Blood.

[7]  L. Badimón,et al.  Aggregated Low-Density Lipoprotein Uptake Induces Membrane Tissue Factor Procoagulant Activity and Microparticle Release in Human Vascular Smooth Muscle Cells , 2004, Circulation.

[8]  L. Horstman,et al.  Elevation of endothelial microparticles, platelets, and leukocyte activation in patients with venous thromboembolism. , 2005, Journal of the American College of Cardiology.

[9]  P. Serruys,et al.  Prevalence, Distribution, Predictors, and Outcomes of Patients With Calcified Nodules in Native Coronary Arteries: A 3-Vessel Intravascular Ultrasound Analysis From Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) , 2012, Circulation.

[10]  Valentin Fuster,et al.  Imaging of atherosclerosis: magnetic resonance imaging. , 2011, European heart journal.

[11]  H. Ogawa,et al.  Significance of a multiple biomarkers strategy including endothelial dysfunction to improve risk stratification for cardiovascular events in patients at high risk for coronary heart disease. , 2009, Journal of the American College of Cardiology.

[12]  R. Touyz,et al.  Microparticles: biomarkers and beyond. , 2013, Clinical science.

[13]  A. Simon,et al.  Circulating Leukocyte-Derived Microparticles Predict Subclinical Atherosclerosis Burden in Asymptomatic Subjects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[14]  H. Lim,et al.  Clinically apparent atherosclerotic disease in diabetes is associated with an increase in platelet microparticle levels , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[15]  J. Kastelein,et al.  Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands. , 2010, Atherosclerosis.

[16]  K. Williams,et al.  Cholesterol Enrichment of Human Monocyte/Macrophages Induces Surface Exposure of Phosphatidylserine and the Release of Biologically-Active Tissue Factor–Positive Microvesicles , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[17]  K. Maquelin,et al.  Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. , 1997, Circulation.

[18]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary. , 2007, Atherosclerosis.

[19]  D. Johns,et al.  Monocyte tissue factor-dependent activation of coagulation in hypercholesterolemic mice and monkeys is inhibited by simvastatin. , 2012, The Journal of clinical investigation.

[20]  G. Vilahur,et al.  Circulating and platelet-derived microparticles in human blood enhance thrombosis on atherosclerotic plaques , 2012, Thrombosis and Haemostasis.

[21]  Françoise Dignat-George,et al.  The Many Faces of Endothelial Microparticles , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[22]  R. Nieuwland,et al.  Circulating microparticles in patients with benign and malignant ovarian tumors. , 2012, Anticancer research.

[23]  J. Witztum,et al.  The role of innate immunity in atherogenesis11 Guest editor for this article was Linda Curtiss, the Scripps Research Institute. Published, JLR Papers in Press, December 22, 2008. , 2009, Journal of Lipid Research.

[24]  E. Guallar,et al.  Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART) , 2011, Lipids in Health and Disease.

[25]  S. Hazen.  Neutrophils, hypercholesterolemia, and atherogenesis. , 2010, Circulation.

[26]  J. Dayer,et al.  Stimulated T cells generate microparticles, which mimic cellular contact activation of human monocytes: differential regulation of pro‐ and anti‐inflammatory cytokine production by high‐density lipoproteins , 2008, Journal of leukocyte biology.

[27]  C. Hack,et al.  Cell-derived Microparticles Circulate in Healthy Humans and Support Low Grade Thrombin Generation , 2001, Thrombosis and Haemostasis.

[28]  E. Wijsman,et al.  A macrophage sterol-responsive network linked to atherogenesis. , 2010, Cell metabolism.

[29]  C. Johnsen,et al.  Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[30]  Tomohiro Sakamoto,et al.  Elevated levels of VE-cadherin-positive endothelial microparticles in patients with type 2 diabetes mellitus and coronary artery disease. , 2005, Journal of the American College of Cardiology.

[31]  A. Mügge,et al.  CD31+/Annexin V+ microparticles in healthy offsprings of patients with coronary artery disease , 2009, European journal of clinical investigation.

[32]  G. Nickenig,et al.  Circulating CD 31 1 / Annexin V 1 microparticles correlate with cardiovascular outcomes , 2011 .

[33]  R. Nieuwland,et al.  Measuring circulating cell‐derived microparticles , 2004, Journal of thrombosis and haemostasis : JTH.

[34]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[35]  E. Sijbrands,et al.  Accelerated subclinical coronary atherosclerosis in patients with familial hypercholesterolemia. , 2011, Atherosclerosis.

[36]  G. Nickenig,et al.  Monocytic microparticles promote atherogenesis by modulating inflammatory cells in mice , 2012, Journal of cellular and molecular medicine.

[37]  G. London,et al.  Predictive value of circulating endothelial microparticles for cardiovascular mortality in end-stage renal failure: a pilot study. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  R Lacroix,et al.  Standardization of platelet‐derived microparticle enumeration by flow cytometry with calibrated beads: results of the International Society on Thrombosis and Haemostasis SSC Collaborative workshop , 2010, Journal of thrombosis and haemostasis : JTH.

[39]  X. Alomar Serrallach,et al.  Coronary computed tomographic angiographic findings in asymptomatic patients with heterozygous familial hypercholesterolemia and null allele low-density lipoprotein receptor mutations. , 2013, The American journal of cardiology.

[40]  R. Paltriccia,et al.  Increased Ratio of CD31+/CD42− Microparticles to Endothelial Progenitors as a Novel Marker of Atherosclerosis in Hypercholesterolemia , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[41]  J. Beckman,et al.  Relationship of Clinical Presentation and Calcification of Culprit Coronary Artery Stenoses , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[42]  B. Binder,et al.  Oxidized Membrane Vesicles and Blebs From Apoptotic Cells Contain Biologically Active Oxidized Phospholipids That Induce Monocyte‐Endothelial Interactions , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[43]  Y. Castier,et al.  Cellular origins and thrombogenic activity of microparticles isolated from human atherosclerotic plaques. , 2007, Journal of the American College of Cardiology.

[44]  C. Boulanger.  Microparticles, vascular function and hypertension , 2010, Current opinion in nephrology and hypertension.

[45]  Shah Ebrahim,et al.  European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit , 2007, European heart journal.

[46]  L. Badimón,et al.  Detection of subclinical atherosclerosis in familial hypercholesterolemia using non-invasive imaging modalities. , 2012, Atherosclerosis.

[47]  Romaric Lacroix,et al.  Plasmatic level of leukocyte-derived microparticles is associated with unstable plaque in asymptomatic patients with high-grade carotid stenosis. , 2013, Journal of the American College of Cardiology.

[48]  C. Bode,et al.  Increased platelet, leukocyte and endothelial microparticles predict enhanced coagulation and vascular inflammation in pulmonary hypertension , 2011, Journal of Thrombosis and Thrombolysis.

[49]  Ildikó Kriszbacher,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, New England Journal of Medicine.

[50]  C. Weber,et al.  Atherosclerosis: current pathogenesis and therapeutic options , 2011, Nature Medicine.

[51]  R. Nieuwland,et al.  The phospholipid composition and cholesterol content of platelet‐derived microparticles: a comparison with platelet membrane fractions , 2005, Journal of thrombosis and haemostasis : JTH.

[52]  Chantal M Boulanger,et al.  Microparticles From Human Atherosclerotic Plaques Promote Endothelial ICAM-1–Dependent Monocyte Adhesion and Transendothelial Migration , 2011, Circulation research.

[53]  R. Hegele,et al.  Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease , 2006, Canadian Medical Association Journal.

[54]  S. Humphries,et al.  Familial hypercholesterolaemia: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[55]  Ken Jacobson,et al.  Monocytic microparticles activate endothelial cells in an IL-1β-dependent manner. , 2011, Blood.

[56]  M. Pocovi,et al.  Molecular characterization of familial hypercholesterolemia in Spain: Identification of 39 novel and 77 recurrent mutations in LDLR , 2004, Human mutation.

[57]  L. Badimón,et al.  Sustained long-term improvement of arterial endothelial function in heterozygous familial hypercholesterolemia patients treated with simvastatin. , 2001, Atherosclerosis.

[58]  J. Kastelein,et al.  Familial Hypercholesterolemia: Present and Future Management , 2011, Current cardiology reports.

[59]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[60]  Mary A Whooley,et al.  Self-reported medication adherence and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. , 2007, Archives of internal medicine.

[61]  N. Key,et al.  Platelet microparticles are heterogeneous and highly dependent on the activation mechanism: Studies using a new digital flow cytometer , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[62]  S. Mause.  Platelet microparticles: reinforcing the hegemony of platelets in atherothrombosis. , 2012, Thrombosis and haemostasis.